Platinum-resistant Ovarian Cancer Terminated Phase 1 / 2 Trials for CRS-207 (DB17323)

Also known as: Platinum drug resistant Ovarian cancer / Platinum-resistant Ovarian Cancer (PROC) / Platinum Resistant Ovarian Cancer

IndicationStatusPhase
DBCOND0068919 (Platinum-resistant Ovarian Cancer)Terminated1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02575807Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal CancerTreatment